News

January 18, 2021January 18, 2021

Less-frequent Dosing of Imfinzi Approved in Europe for Advanced Lung Cancer

News

A less-frequent, fixed dose regimen of Imfinzi (durvalumab) has been approved in the European Union and U.K. to treat adults with locally advanced, inoperable non-small cell lung cancer (NSCLC), announced ... Read more

January 15, 2021January 15, 2021

T-cell Therapy Showing Promise in Synovial Sarcoma Patients in Phase 1 Trial

News

ADP-A2M4, an investigational therapy that uses engineered immune cells to fight cancer, showed an acceptable safety profile and promising effectiveness in people with synovial sarcoma, a rare cancer that develops ... Read more

January 11, 2021January 11, 2021

Personalized AV-GBM-1 Vaccine Shows Promise for Aggressive Brain Cancer

News

Adding AIVITA Biomedical’s experimental and personalized cancer vaccine, AV-GBM-1, to post-surgery standard treatment slows disease progression in adults newly diagnosed with glioblastoma — the most aggressive type of brain cancer ... Read more

January 8, 2021January 8, 2021

Cavrotolimod Plus PD-1 Blockers Showing Efficacy in Advanced Cancers, Trial Reports

News

The investigational therapy cavrotolimod (AST-008), in combination with the PD-1 inhibitor Keytruda (pembrolizumab), was safe and well-tolerated, and showed signs of efficacy in people with advanced solid tumors who failed ... Read more

January 6, 2021January 6, 2021

Tiragolumab-Tecentriq Combo for NSCLC Earns Breakthrough Therapy Status

News

The U.S. Food and Drug Administration (FDA) has granted the designation of breakthrough therapy to a combination of tiragolumab, a novel immunotherapy developed by Genentech, plus Tecentriq (atezolizumab) for the ... Read more

January 4, 2021January 8, 2021

Triple Combo With Libtayo Shows Promise in Hard-to-treat Brain Cancer

News

Combining two experimental cancer vaccines with Libtayo (cemiplimab) promotes strong anti-tumor immune responses and shows early signs of effectiveness in adults newly diagnosed with glioblastoma — the most aggressive type ... Read more

December 21, 2020December 21, 2020

Cancer Vaccines Get FDA Breakthrough Status in Advanced Melanoma Combo Therapy

News

The U.S. Food and Drug Administration (FDA) has granted the designation of breakthrough therapy to a combination treatment of IO Biotech’s lead anti-cancer vaccine candidates IO102 and IO103, plus an ... Read more

December 18, 2020December 18, 2020

Tebentafusp Prolongs Life for Those With Advanced Eye Cancer, Trial Finds

News

Immunocore’s investigational immunotherapy tebentafusp (IMCgp100) is superior to investigator’s choice at prolonging the lives of adults newly diagnosed with metastatic uveal melanoma — a common and hard-to-treat form of eye ... Read more

December 16, 2020December 16, 2020

EU Approval Urged for Bavencio as Maintenance Therapy for Bladder Cancer

News

A European Medicines Agency (EMA) committee has adopted a positive opinion on Bavencio (avelumab), recommending its approval as a first-line maintenance treatment for adults with locally advanced or metastatic bladder ... Read more

December 14, 2020December 14, 2020

Keytruda Approval Recommended in EU as First-line Therapy for Certain Colorectal Cancers

News

Keytruda (pembrolizumab) has been recommended for approval in the European Union (EU) as a first-line treatment for adults with inoperable or metastatic colorectal cancer with certain genetic features. These include ... Read more